Is Replimune Stock a Good Investment?
Replimune Investment Advice | REPL |
- Examine Replimune's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Replimune's leadership team and their track record. Good management can help Replimune navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Replimune's business and its evolving consumer preferences.
- Compare Replimune's performance and market position to its competitors. Analyze how Replimune is positioned in terms of product offerings, innovation, and market share.
- Check if Replimune pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Replimune's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Replimune Group stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Replimune Group is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Mild | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Small | Details | |
Economic Sensitivity | Very regressive towards the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Replimune Stock
Researching Replimune's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.31. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Replimune Group recorded a loss per share of 3.24. The entity had not issued any dividends in recent years.
To determine if Replimune is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Replimune's research are outlined below:
| Replimune Group is way too risky over 90 days horizon | |
| Replimune Group appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (247.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Replimune Group currently holds about 395.08 M in cash with (192.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Replimune Group has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors |
Replimune uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Replimune Group. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Replimune's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 16th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 16th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Replimune's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 442.58 M.Basic technical analysis of Replimune Stock
As of the 25th of August, Replimune holds the Coefficient Of Variation of 1450.03, semi deviation of 13.54, and Risk Adjusted Performance of 0.0605. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Replimune, as well as the relationship between them. Please check Replimune Group variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Replimune Group is priced some-what accurately, providing market reflects its current price of 5.67 per share. Given that Replimune has jensen alpha of 1.26, we recommend you to check out Replimune Group's recent market performance to make sure the company can sustain itself at a future point.Replimune's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Replimune insiders, such as employees or executives, is commonly permitted as long as it does not rely on Replimune's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Replimune insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Replimune's Outstanding Corporate Bonds
Replimune issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Replimune Group uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Replimune bonds can be classified according to their maturity, which is the date when Replimune Group has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| SCGAU 5125 24 SEP 80 Corp BondUS76025LAB09 | View |
Understand Replimune's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Replimune's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0605 | |||
| Market Risk Adjusted Performance | (1.46) | |||
| Mean Deviation | 7.06 | |||
| Semi Deviation | 13.54 | |||
| Downside Deviation | 15.82 | |||
| Coefficient Of Variation | 1450.03 | |||
| Standard Deviation | 17.37 | |||
| Variance | 301.64 | |||
| Information Ratio | 0.063 | |||
| Jensen Alpha | 1.26 | |||
| Total Risk Alpha | (1.03) | |||
| Sortino Ratio | 0.0691 | |||
| Treynor Ratio | (1.47) | |||
| Maximum Drawdown | 126.2 | |||
| Value At Risk | (7.19) | |||
| Potential Upside | 11.24 | |||
| Downside Variance | 250.29 | |||
| Semi Variance | 183.28 | |||
| Expected Short fall | (7.99) | |||
| Skewness | 1.63 | |||
| Kurtosis | 24.01 |
| Risk Adjusted Performance | 0.0605 | |||
| Market Risk Adjusted Performance | (1.46) | |||
| Mean Deviation | 7.06 | |||
| Semi Deviation | 13.54 | |||
| Downside Deviation | 15.82 | |||
| Coefficient Of Variation | 1450.03 | |||
| Standard Deviation | 17.37 | |||
| Variance | 301.64 | |||
| Information Ratio | 0.063 | |||
| Jensen Alpha | 1.26 | |||
| Total Risk Alpha | (1.03) | |||
| Sortino Ratio | 0.0691 | |||
| Treynor Ratio | (1.47) | |||
| Maximum Drawdown | 126.2 | |||
| Value At Risk | (7.19) | |||
| Potential Upside | 11.24 | |||
| Downside Variance | 250.29 | |||
| Semi Variance | 183.28 | |||
| Expected Short fall | (7.99) | |||
| Skewness | 1.63 | |||
| Kurtosis | 24.01 |
Consider Replimune's intraday indicators
Replimune intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Replimune stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Replimune time-series forecasting models is one of many Replimune's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Replimune's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Replimune Stock media impact
There is far too much social signal, news, headlines, and media speculation about Replimune that are available to investors today. This information is accessible both publicly - through Replimune's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Replimune-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Replimune news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Replimune relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Replimune's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Replimune alpha.
Replimune Corporate Management
| Colin Love | Chief Officer | Profile | |
| Christopher Sarchi | Chief Officer | Profile | |
| Carolyn Trott | Senior Assurance | Profile | |
| Pamela Esposito | Chief Business Officer | Profile | |
| Paul Bullock | Chief Head | Profile | |
| Kari Jeschke | Senior Affairs | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Replimune's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.